Document Detail


One-year evaluation of the preventative effect of hydrofluoroalkane-beclomethasone dipropionate on eosinophilic inflammation of asthmatic peripheral airways.
MedLine Citation:
PMID:  16804291     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In asthmatic patients with eosinophilic inflammation of the peripheral airways, appropriate drug delivery to the affected area is required. OBJECTIVE: It was the aim of this study to assess persistent eosinophilic inflammation of the peripheral airways in asthmatic patients, stabilized by the long-term use of dry powder type inhaled steroids, and to evaluate the clinical efficacy of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) over 1 year. METHODS: Seventy-four outpatients with moderate stable asthma were studied for at least 6 months, 37 treated with fluticasone propionate Diskus (FP-DK) and 37 with budesonide Turbuhaler (BUD-TH). The eosinophil count, eosinophil cationic protein (ECP), eotaxin and RANTES levels in 10% hypertonic saline-induced sputum were examined before treatment, as well as 4 weeks, 8 weeks, 6 months and 1 year after switching patients to HFA-BDP. RESULTS: Fifteen patients (40.5%) in the FP-DK group and 12 (32.4%) in the BUD-TH group had eosinophils in induced sputum. The sputum ECP in the eosinophil-positive and the eosinophil-negative groups was 1,510.1 +/- 2,009.3 versus 426.6 +/- 464.1 microg/l (p = 0.037) in the FP-DK group, and 3,850.0 +/- 5,486.2 versus 492.0 +/- 1,150.7 microg/l (p = 0.011) in the BUD-TH group, respectively. Four weeks after the switch to HFA-BDP, the number of eosinophil-positive patients decreased in both groups. Significant reductions in sputum ECP and eotaxin were observed at 8 weeks, and their concentrations continued decreasing for 1 year. CONCLUSION: There is a certain proportion of asthmatic patients for whom long-term treatment with dry powder type steroids may not be suitable; however, their peripheral airway inflammation improved after switching them to HFA-BDP, suggesting its excellent delivery.
Authors:
Hiroyuki Ohbayashi
Publication Detail:
Type:  Journal Article     Date:  2006-06-26
Journal Detail:
Title:  Respiration; international review of thoracic diseases     Volume:  74     ISSN:  0025-7931     ISO Abbreviation:  Respiration     Publication Date:  2007  
Date Detail:
Created Date:  2007-02-23     Completed Date:  2007-04-17     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0137356     Medline TA:  Respiration     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  146-53     Citation Subset:  IM    
Affiliation:
Department of Allergy and Respiratory Medicine, Tohno-Kousei Hospital, Mizunami, Gifu Pref. 509-6101, Japan. ohbayasi@nn.iij4u.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Aerosol Propellants / administration & dosage*
Aged
Asthma / complications,  drug therapy*,  physiopathology
Beclomethasone / administration & dosage*
Bronchitis / complications,  pathology,  prevention & control*
Eosinophilia / pathology,  prevention & control*
Eosinophils / pathology
Female
Follow-Up Studies
Glucocorticoids / administration & dosage*
Humans
Hydrocarbons, Fluorinated / administration & dosage*
Leukocyte Count
Male
Middle Aged
Sputum / cytology
Time Factors
Treatment Outcome
Vital Capacity / physiology
Chemical
Reg. No./Substance:
0/Aerosol Propellants; 0/Glucocorticoids; 0/Hydrocarbons, Fluorinated; 431-89-0/HFA 134a; 4419-39-0/Beclomethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between exhaled breath condensate volume and measurements of lung volumes.
Next Document:  Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a pros...